Algeta ASA : Algeta to Participate in Upcoming Investor Conference

Oslo, Norway, 17 April 2013 - Algeta ASA (OSE: ALGETA), a company focused on the development of novel targeted cancer therapeutics, announces that members of its senior management and IR teams will participate in the following investor conference:

Kempen & Co. 6th Healthcare/Life Sciences Conference
	Date: 23 April 2013
	Participants:
		Thomas Ramdahl (Chief Technology Officer)
		Renate Birkeli (IR)
	Venue: Amsterdam, The Netherlands

###

For further information, please contact:

Mike Booth / Renate Birkeli	[phone]
Communications & Corporate Affairs	[e-mail]
Media enquiries:
Mark Swallow	[phone]
Citigate Dewe Rogerson	[e-mail]
Knut Ekern	[phone]
Gambit Hill & Knowlton	[e-mail]
Kari Watson	[phone]
MacDougall Biomedical Communications	[e-mail]
US investor enquiries:
Tricia Swanson	[phone]
The Trout Group	[e-mail]

About Algeta

Algeta is a company focused on developing novel targeted therapies for patients with cancer based on its alpha-pharmaceutical platform. The Company is headquartered in Oslo, Norway, and has a US subsidiary, Algeta US, LLC, based in Cambridge, MA performing commercial marketing operations in the US. Algeta is listed on the Oslo Stock Exchange (Ticker: ALGETA). For more information please visit www.algeta.com.

This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.